A meta-analysis of the data surrounding Boston Scientific's recently approved stroke-preventing Watchman device concluded that it reduces risk of death from hemorrhagic stroke, cardiovascular death, and major non–procedural-related bleeding compared to patients on long-term use of the blood thinner warfarin.
Boston Scientific promoted new information that its latest spinal cord stimulator is twice as effective as its predecessor at lower back pain relief at the International Neuromodulation Society 12th World Congress in Montreal.
Boston Scientific was ordered to fork over $100 million to a woman who alleged the company's vaginal mesh products caused her undue pain and suffering, a stinging blow for the device giant as it moves to settle claims with patients.
Irish researchers have developed a gel containing clusters of pancreatic cells that they say can control glucose levels for up to 5 years when administered via a minimally invasive injection procedure being developed by medical device bigwig Boston Scientific.
Boston Scientific revealed more details about its leadless pacemaker program, as it seeks to join Medtronic and St. Jude Medical in that market (which does not yet exist in the U.S., where the devices are still being investigated).
Irish researchers are developing an alternative to pancreas transplants as the race to treat diabetes heats up. They are developing a substance containing pancreatic cells embedded in a gel.
Nevro revealed that Boston Scientific is challenging its patent for "selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods," and promised to vigorously defend its intellectual property in the matter.
At its investor day on May 1, Boston Scientific pledged to accelerate sales growth to 3% to 6% and boost its operating margins to 25% by 2017 on the back of a promising product pipeline, like the newly approved Watchman device for preventing stroke and the next generation of its fast selling S-ICD, which reduces implantable defibrillators' reliance on troublesome wires known as leads.
Aegea Medical expects to get a PMA application into the FDA for its water vapor device to treat abnormal uterine bleeding with a $36 million Series C financing. It's already completed enrollment on a multi-center, international pivotal trial that is slated to have final primary endpoint data in February 2016.
In medical devices, it's all about offering value to hospitals as they continue to undergo consolidation in the U.S., thereby enabling them to wield greater buying power. To demonstrate its commitment to addressing that trend, Boston Scientific has added a couple of partnerships intended to improve the usability and value of its products: one with cardiovascular consultancy MedAxiom and another with healthcare data analytics company TogetherMD.